CASPOFUNGIN FOR INJECTION DIN 02460947
Status: Marketed
Holder: JUNO PHARMA CANADA INC.
Molecule: CASPOFUNGIN (CASPOFUNGIN ACETATE)
Available to quote
Health Canada record
| Active ingredient(s) | CASPOFUNGIN (CASPOFUNGIN ACETATE) 50 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J02AX04 CASPOFUNGIN |
| Original market date | 19-Apr-2017 |
| Current status date | 27-Apr-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Juno Pharma Canada Inc. — licence 3-002916, currently licensed, last inspection rating C (2025-11-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CASPOFUNGIN (CASPOFUNGIN ACETATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02244266 | CANCIDAS | MERCK CANADA INC | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 70 MG | Marketed |
| 02456125 | CASPOFUNGIN ACETATE FOR INJECTION | STERIMAX INC | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 70 MG | Approved |
| 02456133 | CASPOFUNGIN ACETATE FOR INJECTION | STERIMAX INC | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 50 MG | Approved |
| 02486997 | CASPOFUNGIN FOR INJECTION | FRESENIUS KABI CANADA LTD | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 70 MG | Marketed |
| 02460955 | CASPOFUNGIN FOR INJECTION | JUNO PHARMA CANADA INC. | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 70 MG | Marketed |
| 02486989 | CASPOFUNGIN FOR INJECTION | FRESENIUS KABI CANADA LTD | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 50 MG | Marketed |
| 02244265 | CANCIDAS | MERCK CANADA INC | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 50 MG | Cancelled Post Market |
| 02389207 | CASPOFUNGIN ACETATE FOR INJECTION | SANDOZ CANADA INCORPORATED | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 70 MG | Cancelled Pre Market |
| 02389193 | CASPOFUNGIN ACETATE FOR INJECTION | SANDOZ CANADA INCORPORATED | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 50 MG | Cancelled Pre Market |
| 02448815 | CASPOFUNGIN POWDER FOR INJECTION | TEVA CANADA LIMITED | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 50 MG | Cancelled Pre Market |
| 02448823 | CASPOFUNGIN POWDER FOR INJECTION | TEVA CANADA LIMITED | Powder For Solution | CASPOFUNGIN (CASPOFUNGIN ACETATE) 70 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37404 | 2026-04-27 | Abbreviated New Drug Submission (ANDS) | Administrative: Merger/Buy-out |
| 32386 | 2023-12-20 | Supplement to an Abbreviated New Drug Submission (SANDS) | Update to Labels |
| 25911 | 2021-05-25 | Abbreviated New Drug Submission (ANDS) | UPDATES TO LABELLING MATERIALS. MANUFACTURER NAME CHANGE |
| 19171 | 2017-04-18 | Abbreviated New Drug Submission (ANDS) |